Research programme: ADAM8 inhibitors - Cancer Research Technology/MedivirAlternative Names: ADAM8 inhibitors - Medivir
Latest Information Update: 24 Nov 2015
At a glance
- Originator Kings College London
- Developer Cancer Research Technology; Kings College London; Medivir AB; TransMIT Gesellschaft fur Technologietransfer mbH
- Class Small molecules
- Mechanism of Action ADAM protein inhibitors; Metalloprotease inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Pancreatic cancer